Diseases & Longevity · File 11

Arterial hypertension. The highest-weight modifiable factor globally — asymptomatic until damage.

Arterial hypertension is the highest-weight modifiable risk factor globally for stroke, ischemic heart disease, heart failure, chronic kidney disease, and dementia. Licher et al. (PLoS Med 2019) showed its absence — alongside not smoking and not being overweight — associates with +9 years delay in first chronic disease diagnosis. SPRINT 2015 redefined the target to <120/80 in high-risk.

Why HTN is the most underestimated longevity factor

Hypertension is the silent killer par excellence — no symptoms until organ damage appears (microalbuminuria, ventricular hypertrophy, retinopathy, vascular cognitive decline). That silent latency is exactly what makes it the central target of longevity medicine: there are 10-20 years of window to measure and modulate before damage is visible.

The Rotterdam study (Licher et al., PLoS Med 2019, n=≈9,000) quantified something decisive: absence of hypertension, alongside not smoking and not being overweight, associated with +9 years delay in first chronic disease diagnosis. SPRINT 2015 (NEJM) demonstrated that <120 mmHg systolic target reduces CV events and mortality ~27% in high-risk patients. The useful conversation is not 'what is my pressure?' — it is 'what is my trajectory?'.

HTN doesn't hurt. Its absence delays the first chronic disease by 9 years. That number defines the priority.
Population weight · INTERSTROKE

The global weight, in numbers

Quantitative HTN data come from Global Burden of Disease, INTERSTROKE, Framingham, and modern meta-analyses. These points sustain clinical priority.

  • Global prevalence

    1.4 mil millones

    Approximately 1.4 billion adults worldwide have HTN (NCD-RisC 2017). Only 50% know their diagnosis, and only 20% have it controlled at target.
    — NCD-RisC, Lancet 2017

  • Population weight in stroke

    ~35% del riesgo

    Hypertension alone explains approximately 35% of population stroke risk — the highest-weight modifiable factor among the 10 INTERSTROKE.
    — O'Donnell et al., Lancet 2010

  • SPRINT — redefined target

    ↓27% mortalidad CV

    SPRINT 2015 (NEJM): <120/80 mmHg target reduces major CV events 25% and CV mortality 27% vs <140 mmHg in patients >50 with high CV risk.
    — SPRINT Research Group, NEJM 2015

  • NCD delay if controlled

    +9 años · Licher 2019

    Rotterdam study: absence of HTN + no smoking + no overweight associated with +9 years delay in first NCD diagnosis. HTN is the factor with greatest modifiable impact on disease-free longevity.
    — Licher et al., PLoS Med 2019

Chap. 03 · HTN target organs

Impact on target organs and quality of life

Poorly controlled HTN deteriorates five systems: cerebrovascular, cardiac, renal, ocular, and cognitive. The deterioration is cumulative and silent — that is why measuring matters more than waiting for the symptom.

  • Cerebrovascular

    Ictus + demencia vascular

    HTN is the highest-weight factor for ischemic stroke, hemorrhagic stroke, small vessel disease, and vascular dementia. Midlife hypertension predicts dementia 20-30 years later.
    — Lancet Commission 2024; INTERSTROKE 2010

  • Cardiac

    HVI + IC + IAM

    Chronic HTN causes left ventricular hypertrophy, diastolic dysfunction, and heart failure with preserved ejection fraction (HFpEF). Cumulative burden predicts MI and sudden death.
    — Framingham; SPRINT 2015

  • Renal

    Top 2 causa ERC

    HTN is the second cause of chronic kidney disease (after diabetes), and its control significantly delays progression to end-stage CKD. Microalbuminuria is an early damage marker.
    — KDIGO 2024; NCD-RisC 2017

  • Cognitive and functional

    Factor 2 Lancet Commission

    HTN is one of 14 modifiable factors identified by Lancet Commission 2024 for dementia prevention. Sustained midlife control significantly reduces cognitive risk in old age.
    — Livingston et al., Lancet 2024

What we don't offer — and what we do

Wellness Care does not replace the cardiologist in pharmacological management of hypertension. Drug choice, dose titration, and follow-up of established hypertensive patients belong to the specialist. What we do is what the conventional model rarely addresses with the depth it deserves: the pre-clinical trajectory, subclinical target organ damage, and shared biological axes with other cardiometabolic diseases.

We evaluate patients with borderline HTN, newly diagnosed, or long-standing with suspected subclinical damage through advanced biomarker panel — lipid profile (ApoB, Lp(a)), renal function (cystatin C, microalbuminuria), inflammaging (hsCRP), metabolic profile, ABPM, and organ damage. We design an integrated plan (structured lifestyle intervention + optimization of cardiologist management when applicable + longitudinal follow-up). In coordination, not in parallel.

HTN is not a number — it is a trajectory. And that trajectory is measured with ABPM, subclinical damage, and cardiovascular longevity biomarkers.
How we measure it

How HTN is evaluated
at Wellness Care

Before proposing any adjustment: we measure trajectory, subclinical damage, and biological axes shared with the cardiometabolic cluster.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the HTN conversation in longevity medicine — SPRINT, Licher Rotterdam, Lancet Commission 2024, and global epidemiological data.

«Objetivo <120 mmHg sistólica reduce eventos CV mayores 25% y mortalidad CV 27% vs <140 mmHg en pacientes >50 años con alto riesgo.»
NEJM · 2015
SPRINT Research Group, NEJM 2015
Redefinición del objetivo
«La ausencia de hipertensión, junto con no fumar y no tener sobrepeso, se asoció a +9 años de retraso en el primer diagnóstico de NCD.»
PLoS Med · 2019
Licher et al., PLoS Med 2019
Estudio Rotterdam · longevidad libre de NCD
«La hipertensión es uno de los 14 factores modificables identificados para prevención de demencia — su control sostenido a mediana edad es prioridad.»
Lancet · 2024
Livingston et al., Lancet 2024
Lancet Commission · 14 factores

Frequently asked questions about arterial hypertension

The most recurrent questions about HTN, modern targets (SPRINT 2015), ABPM, subclinical damage, and why longevity medicine sees HTN as trajectory, not isolated number.

01

What is today's blood pressure target?

ACC/AHA 2017 guidelines and ESC/ESH 2023 European update recommend:

· <130/80 mmHg in most adults with HTN

SPRINT 2015 demonstrated <120/80 reduces major CV events 25% in patients >50 with high risk.

Individual target depends on age, comorbidities, tolerance, and baseline risk — that is medical decision.

02

Why insist on ABPM if you measure me in office?

Because office measurement has two clinically important errors:

· White-coat HTN — overestimates in office vs ambulatory
· Masked HTN — normal in office, elevated in ambulatory (particularly nocturnal)

24-hour ABPM captures both errors and provides information on nocturnal pattern:

· Dipper (normal)
· Non-dipper
· Reverse dipper

The pattern is an independent predictor of CV events and vascular dementia.

03

What lifestyle changes really lower BP?

Interventions with demonstrated effect:

· DASH or Mediterranean diet → -8 to -14 mmHg systolic
· Sodium reduction (<2,300 mg/day) → -2 to -8 mmHg
· Weight loss → ~-1 mmHg per kg
· Regular aerobic exercise → -4 to -9 mmHg
· Alcohol restriction → -2 to -4 mmHg
· Stress and sleep management

Combined interventions can reduce 20-30 mmHg in motivated patients — but require structured support.

04

Does HTN cause dementia?

Midlife HTN is one of the 14 modifiable factors identified by the Lancet Commission 2024 for dementia prevention.

Multiple longitudinal cohorts (ARIC, Whitehall II, Framingham) show that poorly controlled HTN at 40-60 predicts cognitive decline and dementia 20-30 years later.

Underlying biology:

· Small vessel disease
· Leukoaraiosis
· Silent micro-infarcts

05

Which biomarkers measure HTN organ damage?

In longevity medicine we evaluate:

· Microalbuminuria and albumin/creatinine ratio (early renal damage)
· Cystatin C and eGFR (renal function)
· ECG with LVH estimated
· Echocardiogram when indicated (LVH, diastolic function)
· Fundus (hypertensive retinopathy)
· ABPM with nocturnal pattern
· Advanced lipid profile — ApoB, Lp(a)
· Inflammaging — hsCRP, fibrinogen

These markers appear before the clinical event.

06

When should I consult?

A structured assessment is worthwhile if you have:

· Borderline HTN (130-140 systolic)
· Newly diagnosed HTN
· Long-standing HTN with suspected subclinical damage
· Family history of early HTN or early CV event
· Difficulty reaching targets
· You want to confirm the pattern with ABPM and biomarkers

The assessment does not replace your cardiologist — it complements them with the longevity view.

9 years of modifiable delay

HTN doesn't hurt. Its absence delays the first chronic disease by 9 years. That number defines priority.

Measure ABPM with nocturnal pattern, evaluate subclinical damage, integrate with cardiologist management, and work the biological axes of the cardiometabolic cluster — that is what's missing in the 7-minute consultation.

Poorly controlled HTN or suspected organ damage?

Book a comprehensive hypertension assessment

We evaluate cardiovascular profile, endothelial function, ABPM, renal profile, subclinical organ damage (microalbuminuria, ECG, fundus), inflammatory profile, and comorbidities. The assessment does not replace cardiology — it complements it with the longevity view.

Book cardiovascular assessment